36

Therapeutic advances in breast cancer have considerably improved survival in young patients, thus raising new issues concerning fertility and parenthood. Access to an oncofertility consultation prior to gonodotoxic treatments is now a legal requirement (bioethics laws of 2004 and 2011; Cancer Plan 2014–2019). Depending on the patient and the oncological context, cryopreservation of oocytes, embryos, or ovarian tissue may be discussed. However, data on pregnancies and births after fertility preservation show that the use of preserved gametes remains low. Even though the pregnancy rate is significantly lower after breast cancer, patients usually conceive spontaneously, and the use of assisted reproductive technologies (ART) remains moderate. Moreover, the oncological safety of posttreatment pregnancies is reassuring overall, even for hormone-dependent tumors, provided at least a two-year interval is observed after treatment. Particular attention should be paid to vascular obstetric complications (gestational hypertension, preeclampsia), especially in patients who have previously undergone chemotherapy. Breastfeeding is possible in most cases and does not increase the risk of recurrence. At present, there is no specific follow-up program for children born after fertility preservation for breast cancer. A program is currently underway in France to monitor the neurodevelopment of vulnerable children up to the age of seven.